• Home
  • Company
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Advisors
  • Pipeline
    • AMHR2 and GM102
    • GamaMabs Pharma Technology
  • News and Publications
    • Press Releases
    • Scientific Publications
    • Others Publications
    • Careers
  • Contact us

Archives

A First-In Human study of monoclonal antibody GM102 in patients with Anti-Müllerian-Hormone-Receptor II (AMHRII) positive gynecological cancers

  • 11 June 2018
  • Scientific publications

Poster # 269_ ASCO 2018

Post navigation

← GamaMabs Pharma to present at 2018 ASCO annual meeting results from the First-In-Human clinical study of GM102 in advanced gynecological cancers GamaMabs Pharma starts a phase 2 study of monoclonal antibody GM102 in patients with advanced or metastatic colorectal cancer →
© copyright 2020 - GamaMabs - All rights reserved Website by PICTAO